Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Young-Hyuck ImBulent KarabulutKeun Seok LeeByeong-Woo ParkAditya AdhavHavva Yesil CinkirHikmat Abdel-RazeqYuan-Ching ChangSercan AksoySeock-Ah ImJoon JeongYeesoo ChaeJames BowlesKhemaies SlimaneHongling XueSung-Bae KimPublished in: Breast cancer research and treatment (2021)
The safety and efficacy results from EVEREXES trial are consistent to data previously reported in BOLERO-2. These results support that EVE + EXE could be a viable treatment option for the postmenopausal women with HR+, HER2 - ABC in Asian region.
Keyphrases
- metastatic breast cancer
- locally advanced
- bone mineral density
- squamous cell carcinoma
- rectal cancer
- study protocol
- neoadjuvant chemotherapy
- clinical trial
- electronic health record
- radiation therapy
- phase iii
- breast cancer risk
- big data
- phase ii
- randomized controlled trial
- postmenopausal women
- lymph node
- double blind